said that a network of little-known drug suppliers and distributors sold illicit and potentially dangerous fake versions of its HIV medicines that ended up in pharmacies and in the hands of patients.
The company uses the word “counterfeit” to include genuine medications that have faked documentation or altered packaging, as well as fake pills.Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.The U.S. pharmaceutical supply chain is considered among the world’s safest, and counterfeits most commonly make their way to patients via online pharmacies or sometimes after being smuggled across the U.S.-Mexico border. But U.
Such seizures, which defendants aren’t aware of in advance, can be a quicker way of getting products off the market than through criminal-law channels, said Randy Gaw, who has represented wholesalers in Lanham Act cases but isn’t involved in the Gilead dispute. Gilead’s allegations pertain primarily to two of its HIV treatments, Biktarvy and Descovy, the latter of which is also used to prevent HIV infection. The drugs are projected to have had $10.2 billion in combined sales last year. Descovy and Biktarvy arrive at pharmacies in sealed bottles, so pharmacists have no role in filling the containers.
Mr. Jerominski said White Cross purchased Biktarvy from Safe Chain Solutions LLC, a wholesale distributor based in Maryland, because it was charging a cheaper price than its primary wholesaler.An attorney for Safe Chain, which is a defendant in the suit, said his clients strongly disagree with Gilead’s allegations and that one of the company’s founding principles is protecting the safety and integrity of the pharmaceutical supply chain.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJ - 🏆 98. / 63 Read more »
Source: WSJ - 🏆 98. / 63 Read more »
Source: WSJ - 🏆 98. / 63 Read more »
Source: ABC7Chicago - 🏆 284. / 63 Read more »
Source: WSJ - 🏆 98. / 63 Read more »
Source: enews - 🏆 466. / 52 Read more »